Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy

<p>Abstract</p> <p>5-Aza-2′-deoxycytidine (5-AZA-CdR, decitabine), an epigenetic drug that inhibits DNA methylation, is currently used to treat myelodysplastic syndrome (MDS), and is under investigation for treating acute myeloid leukemia (AML) and other malignancies. 5-AZA-CdR can...

Full description

Bibliographic Details
Main Authors: Karahoca Metin, Momparler Richard L
Format: Article
Language:English
Published: BMC 2013-02-01
Series:Clinical Epigenetics
Subjects:
Decitabine
5-aza-2’-deoxycytidine
Epigenetics
AML
MDS
DNA methylation
Pharmacokinetics
Pharmacodynamics
Online Access:http://www.clinicalepigeneticsjournal.com/content/5/1/3

Internet

http://www.clinicalepigeneticsjournal.com/content/5/1/3

Similar Items